Beta Bionics (BBNX) Cash & Equivalents (2023 - 2026)

Beta Bionics has disclosed Cash & Equivalents across 4 years of filings, most recently posting $44.3 million for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 26.35% year-over-year to $44.3 million; the TTM figure through Jun 2026 stood at $44.3 million (up 26.35% YoY), while the FY2025 annual figure was $31.6 million, up 3.76% from the prior year.
• Cash & Equivalents came in at $44.3 million for Q2 2026 at Beta Bionics, up from $30.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $44.3 million in Q2 2026 to a low of $13.0 million in Q2 2024.
• Average Cash & Equivalents over 4 years is $30.2 million, with a median of $30.4 million recorded in 2024.
• Year-over-year, Cash & Equivalents soared 169.21% in 2025 and retreated 28.85% in 2026.
• Over 4 years, Cash & Equivalents stood at $26.6 million in 2023, then advanced by 14.55% to $30.4 million in 2024, then gained by 3.76% to $31.6 million in 2025, then soared by 40.35% to $44.3 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $44.3 million in Q2 2026, $30.2 million in Q1 2026, and $31.6 million in Q4 2025.